A naturally occurring signaling molecule called C-type natriuretic peptide, or CNP, was shown to reduce the severity of PAH.
COPENHAGEN, Denmark, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced topline results from Week 52 of COACH, the first Phase 2 clinical trial to evaluate ...
CenterPoint Energy CNP benefits from rising electricity consumption, driven by the rapid electrification of transportation and buildings, along with increasing investments in renewable energy. Given ...
– Combination therapy was generally well tolerated, with generally mild treatment-emergent adverse events (TEAEs), consistent with TransCon CNP and TransCon hGH monotherapies – Ascendis to host ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results